Overview

AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA

Status:
RECRUITING

Trial end date:
2028-01-01

Target enrollment:

Participant gender:

Summary

This is a phase II, single-arm, multicenter study to evaluate the activity and safety of durvalumab in combination with carboplatin or cisplatin plus etoposide in patients with treated ES-EPSCC.

Phase:

PHASE2

Details

Lead Sponsor:

Gruppo Oncologico Italiano di Ricerca Clinica

Treatments:

durvalumab
Etoposide